Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9149858 | 0.89 | HTR6 (0.40) | HTR6BRD4HTR2CHTR2BALDH1A1 | |
| SCHEMBL2905155 | 0.77 | BRD4 (0.65) | HTR6BRD4HTR2CHTR2BALDH1A1 | |
| SCHEMBL8799345 | 0.74 | HTR6 (0.37) | HTR6HTR2CHTR2BALDH1A1SMN1; SMN2 | |
| SCHEMBL8799530 | 0.74 | HTR6 (0.37) | HTR6HTR2CHTR2BALDH1A1SMN1; SMN2 | |
| SCHEMBL8799701 | 0.74 | HTR6 (0.37) | HTR6HTR2CHTR2BALDH1A1SMN1; SMN2 | |
| SCHEMBL2904988 | 0.73 | HTR6 (0.50) | HTR6HTR2CHTR2BALDH1A1MAPT | |
| SCHEMBL2953559 | 0.73 | ALDH1A1 (0.56) | ALDH1A1MAPT | |
| SCHEMBL30303079 | 0.72 | GAA (0.40) | BRD4ALDH1A1POLBMAPT | |
| SCHEMBL1555141 | 0.72 | GAA (0.40) | BRD4ALDH1A1POLBMAPT | |
| SCHEMBL14201231 | 0.72 | MAOB (0.39) | HTR6HTR2CHTR2BALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1797051-B1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| EP-1797051-B1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378415-B2 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1797051-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006037481-A1 | BENZOXAZINE AND QUINOXALINE DERIVATIVES AND USES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106012-A1 | Benzoxazine and quinoxaline derivatives and uses thereof | XDH, PDHX, HAX1 | HTR6 1421/4885BRD4 455/4885HTR2C 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.